Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ovarian Neoplasms × inavolisib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Neoplasm Metastasis 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumors 1 PIK3CA-Mutated Cancers 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Castration-Resistant Prostate Cancer 1 HER2-positive Breast Cancer 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 271 Carboplatin 269 Bevacizumab 144 pembrolizumab 84 liposomal doxorubicin 82 Gemcitabine 82 Cyclophosphamide 81 olaparib 73 Cisplatin 72 Topotecan 71 niraparib 52 Docetaxel 48 Doxorubicin 43 Drug Therapy 37 fludarabine 35 Taxes 35 Nivolumab 32 Filgrastim 31 Etoposide 28 Specimen Handling 27 Magnetic Resonance Spectroscopy 24 Peripheral Blood Stem Cell Transplantation 23 durvalumab 21 Immunoglobulin G 21 Disulfides 21 Hyperthermic Intraperitoneal Chemotherapy 20 aldesleukin 19 atezolizumab 18 Albumin-Bound Paclitaxel 18 apatinib 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04931342 2026-03-10

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡